

REFERENCES

- Aiuti A., Salvin S., Aker M., Ficara F., Docola S., Mortcllaro A., Morccki S., Andolfi G., Tabucchi A., Carlucci F., Marinello E., Cattanco F., Vai S., Servida P., Minicro R., Roncarolo M.G. and Bordignon C. (2002):** Correction Of ADA-SCID by stem cell gene therapy combined with nonmyloablative conditioning. *Science* ; 296: 2410- 2413.
- Aiuti A.,Vai S., Mortellaro A., Casorati G.,Ficara F. Andolfi G., Ferrari G., Tabucchi A., Calucci F., Ochs IID., Notarangelo L.D., Roncarolo M.G. and Bordignon C. (2002):** Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. *Nat Med* ; 8: 423-425.
- Aiuti A., Ficara F., Cattanco F., Bordignon C. and Roncarolo M.G. (2003):** Gene therapy adenosine deaminase deficiency. *Curr Opin Allergy Clin Immunol* ; 3:461-6.
- Alberts B., Bray D. and Lewis J. (1994):** *Molecular Biology of the Cell. Hematology* ,3rd (ed). Garland Pub., N.Y ; 335-336.
- Alexander M Y, Brosnan M J, Hamilton C A, et al. (2002):**Gene transfer of endothelial nitric oxide synthase but not Cu/Zn superoxide dismutase restores nitric oxide availability in the SHRSP. *Cardiovasc Res.*; 47(3):609–617.
- Alvarez-Vallina L.(2001):** Genetic approaches for antigen-selective cell therapy. *Curr Gene Ther* ; 1: 385-397.

- Anderson W.F.(1995):** End-of-the-year potpourri-1995. *Hum Gene Ther* ; 6: 1505-1506.
- Andreansky S.S., Sorcoceanu L., Flotte E.R., Chou J., Markert J. M., Gillespie G.Y., Roizman B. and Whitley R.J. (1997):** Evaluation of genetically engineered herpes simplex virus as oncolytic agents for human malignant brain tumors. *Cancer Research* ; 57: 1502-1509.
- Antoine C.S., Muller A. and Cant B. (2003):** Long-term survival and -transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience. *Lancet* ; 361:553-560.
- Aragão F.J.L., Barros L.M.G., Brasileiro A.C.M., Ribeiro S.G., Smith F.D., Sanford J.C., Faria J.C. and Rech E.L. (1996):** Inheritance of foreign genes in transgenic bean (*Phaseolus vulgaris* L) co-transformed via particle bombardment .*Theoretical and Applied Genetics* ; 93: 142-150 .
- Arruda V.R., Stedman H.H. and Nichols T.C. (2005):** Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. *Blood* ; 105: 3458-3464.
- Asahara T, Chen D, Tsurumi Y, et al.(1996)** Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF₁₆₅ gene transfer. *Circulation.*;94(12):3291–3302.

Balague C., Zhou J. and Dai Y. (2000): Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. *Blood*; 95:820-828.

Baim D S, Wahr D, George B, et al. (2002): Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. *Circulation*. ;105(11):1285–1290.

Baker A H, Mehta D, George S J, Angelini G D.(1999): Prevention of vein graft failure: potential applications for gene therapy. *Cardiovasc Res.*;35(3):442–450.

Baker A H, Zaltsman A B, George S J, Newby A C.(1998): Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. *J Clin Invest* ;101(6):1478–1487.

Balmer U., Naldini L ., Kafri T. and Gage F.H.(1997): Highly efficient and sustained gene transfer in adult neurones with a lentivirus vector. *Journal of Virology* ; 71: 6641-6649.

Barbara, Mitta., Cornelia C. ,Weber., Martin and Fussenegger (2005): In vivo transduction of HIV-1-derived lentiviral particles engineered for macrolide-adjustable transgene expression. *The Journal of Gene Medicine* ; 7(11) : 1400 – 1408.

- Barese C.N., Goebel W.S. and Dinauer M.C. (2004):** Gene therapy for chronic granulomatous disease. *Expert Opin Biol Ther* ; 4: 1423–1434.
- Barnes M.N., Deshane J.S, Rosenfield M. and Alvarez R.D. (1997):** Gene therapy and ovarian cancer: a review. *Obstetrics and Gynecology* ; 89:145-155.
- Baum C., Dullmann J., Li Z., Fehse B., Meyer J. and Williams D.A. (2003):** Side effects of retroviral gene transfer into hematopoietic stem cells. *Blood*; 101: 2099-3014.
- Baum C., von Kalle C. and Staal F.J. (2004):** Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. *Mol Ther*; 9: 5-13.
- Baumgartner I, Pieczek A, Manor O, et al.(1998):** Constitutive expression of phVEGF₁₆₅ after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. *Circulation*. 1998;97(12):1114–1123.
- Bickle T. and Krüger D. (1993):** Biology of DNA restriction. *Microbiol Rev* ; 57: 434-50.
- Blaese R.M., Culver K.W. and Anderson W.F. (1990):** The ADA human gene therapy clinical protocol. *Hum Gene Ther* ; 1: 331-337.
- Bodine D.M., Karlsson S. and Nienhui A. (1989):** Combinatin of interleukin -3 and 5 preservers stem cell function in culture and enhances retro-virus mediated gene transfer into hematopoietic stem cells. *Pro Natl Acad Sci USA*; 86:8897.

- Bond M, Murphy G, Bennett M R, Newby A C, Baker A H.(2002):** Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. *J Biol Chem.*;277(16):13787–13795.
- Bordignon C. L.D., Notarangelo N., Nobili G., Ferrari G., Casorati P., Panina E., Mazzolari D., Maggioni C., Rossi P., Servida A.G., Ugazio and F.M.. Mavilio (1995):** Gene therapy in peripheral blood lymphocyte and bone marrow for ADA – immunodeficiency patients. *Science*; 270: 470-475.
- Boucher, RC (1999):** Status of gene therapy for cystic fibrosis lung disease. *J Clin Invest*;103,441-445
- Britta W. (1999):** Immunogenetic properties of genes. *Acta Oncologica*; 38: 309-311.
- Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S. and Tucker E.E. (1994):** Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. *N Engl J Med*; 331:567-73.
- Buchsacher G.L. (2001):** Introduction to retroviruses and retroviral vectors. *Somat Cell Mol Genet* ; 26: 1-11.
- Budker V., Zhang G., Danko I. And Wolff J. (1998):** The efficient expression of intravascularly delivered DNA in rat muscle . *Gene Therapy* ; 5:272-276.

- Bueler, H (1999):**Adeno-associated viral vectors for gene transfer and gene therapy. *Biol Chem* 1999;380,613-622
- Bukrinsky M.I., Haggerty S. and Dempsey M.P. (1993):** A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. *Nature* ; 365: 666-669.
- Cai Q., Rubin J.T., Lotze M.T. (1995):** Genetically marking human cells--results of the first clinical gene transfer studies. *Cancer Gene Ther*; 2:125-136.
- Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Le Deist F., Fischer A.(2000):** Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science*; 288: 669-672.
- Celletti F L, Waugh J M, Amabile P G, Brendolan A, Hilfiker P R, Dake M D.(2003):** Vascular endothelial growth factor enhances atherosclerotic plaque progression. *Nat Med*. 2003;7(4):425–429.
- Chadwick D.R. and Lever A. M. L. (2000):** Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. *Gene Therapy* ; 7:. 1362-1368.
- Chao H., Mao L., Bruce A.T. and Walsh C.E. (2000):** Sustained expression of human factor VIII in mice using a parvovirus-based vector. *Blood* ; 95:1594-1599.

- Chao J, Chao L.(2000):** Kallikrein gene therapy: a new strategy for hypertensive diseases. *Immunopharmacology*. 2000;36(2-3):229–236.
- Christopher Haslett ,Edwin R.chilvers,Nicholas A.Boon , Nicki R. Colledge , John A. A. Hunter (Davidsons), Edinburgh London(2004) ,** New Yourk Oxford Philadelphia St Louis Sydney Toronto .
- Chuah M.K., Schiedner G. and Thorrez L. (2003):** Therapeutic Factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors . *Blood* ; 101: 1734-1743.
- Connor J.M and Ferguson M.A. (1994):** Human Genetics. In *Essential medical genetics* , 4th(ed). Black well scientific publication. Oxford; 1112-1120.
- Cournoyer D. and Caskey C.T.(1990):** Gene transfer into humans : a first step. *N Engl J Med*; 323: 601.
- Cournoyer D. and Caskey C.T.(1993):** Gene therapy of the immune system. *Annu Rev Immunol* ; 11: 297-329.
- Crystal R.G., McElvaney N.G. and Rosenfeld M.A. (1994):** Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. *Nat Genet* ; 8:42-51.
- Dettweiler U. and Simon P. (2001):** Points to consider for ethics committees in human gene therapy trials. *Bioethics* ; 15: 491-500.

- Dinauer M. (2003):** The phagocyte system and disorders of granulopoiesis and granulocyte function. In: Nathan D., Orkin S., Ginsburg D., Look A., Nathan and Oski's (eds). Hematology of Infancy and Childhood , 6th (ed). W.B. Saunders Company. Philadelphia; 923–1010.
- Dobbelstein M. (2003):** Viruses in therapy—royal road or dead end. *Virus Res* ; 92: 219-221.
- Doherty A. and Suh S. (2000):** Structural and mechanistic conservation in DNA ligases. *Nucleic Acids Rev* ; 28: 4051-8.
- Donnelly J.J., Ulmer J.B., Shiver J.W. and Liu M.A. (1997):** DNA vaccines. *Annu Rev Immunol* ; 15:617-48.
- Dow, SW, Fradkin, LG, Ligitt, DH, et al (1999)** Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. *J Immunol*;163,1552-1561
- Drake. and John W. (1991):** Spontaneous Mutation. *Annual Review of Genetics* ; 25: 125-46.
- Dranoff G. (1993):** Vaccination. with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proc Natl Acad Sci USA* ; 90: 3539-3543.
- Dubinett, SM, Miller, PW, Sharma, S, et al (1998):**Gene therapy for lung cancer. *Hematol Oncol Clin North Am* 1998;12,569-594
- During M.J., Naegele J.R., OMalley K.L. and Geller A.I. (1994):** Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. *Science*; 266: 1399-1403.

Dynlach B.D. (1997): Regulation of transcription by proteins that control the cell cycle. *Nature* ; 389: 149-152 .

Egger J. and Wilson J. (1992): Mitochondrial inheritance in mitochondrially mediated disease. *New Eng J Med* ; 309: 142-146.

Ehrenfeld. and David. (2006): Transgenics and Vertebrate Cloning as Tools for Species Conservation . *Conservation Biology* ; 20 (3): 723-732.

Emery A.E.H. and Muller R.F. (1992): Recombinant DNA : principles and applications elements of medical genetics, 8th (ed). ELBS with Churchill-livingstone. N.Y; 220.

Emery A.E.H. and Riomin D.L.(1992): Nucleic acid function . In, Sofaer, J.A. Black Isobel and Mukusick(editors) .principles and practice of medical genetics , 2nd (ed). W.B. Saunders Company . N.Y ; 157-160.

Ennist, DL(1999): Gene therapy for lung disease. *Trends Pharmacol Sci*;20,260-266

Fan L, Drew J, Dunckley M G, Owen J S, Dickson G.(2000): Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors. *Gene Ther.* 2000;5(10):1434–1440.

Fangman W.L. and Brewer B.A. (1992): Question of time; replication origins of eukaryotic chromosomes. *Cell* ;71: 363–36.

- Fanning G., Amado R. and Symonds G. (2003):** Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen . J Gene Med; 5(8):645-53.
- Federoff H. J., Geschwind M. D., Geller A. I. and Kessler J. A. (1992):** Expression of nerve factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci USA ;89: 1636-1640.
- Feldman S.H. (2003):** Components of gene therapy experimentation that contribute to relative risk. Comp Med ; 2:147-58.
- Feng M., Jackson W.H., Goldman C.K. (1997):** Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotech ; 15: 866-870.
- Fennell J P, Brosnan M J, Frater a J, et al.(2004):** Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension. Gene Ther. 2004; 9(2):110–117.
- Ficara F.D.B., Superchi R. J., Hernandez C., Mocchetti N., Carballido G., Andolfi S., Deola A., Combo C., Bordignon J. M., Caballido M.G., Roncarolo. and Aiuti A. (2004):** IL-3 OR IL-7 increase ex vivo gene transfer efficiency in ADA- SCID BM CD34+ cells while maintaining in vivo lymphoid potential. Mol Ther; 10: 1096-1108.
- Fillat C., Carrio M., Cascante A. and Sangro B. (2003):** Suicide gene therapy mediated by the herpes simplex virus thymidine kinase

gene/ganciclovir system: fifteen years of application. *Curr Gene Ther* ; 3: 13-26.

Findeis M.A., Wu C.H. and Wu G.Y. (1994): Ligand-based carrier systems for delivery of DNA to hepatocytes. *Methods in Enzymology* ; 247: 341-351.

Fisher K.J., Jooss K., Alston J., Yang Y., Haecker S. E., High K., Pathak R., Raper S. E. and Wilson J. M. (1997): Recombinant adeno-associated virus for muscle directed gene delivery. *Nature Medicine* ., 3: 306-316.

Flotte T R, Afione S A, Zeitlin P L.(1994): Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. *Am J Respir Cell Mol Biol.*;11(5):517–521.

Forough R, Koyama N, Hasenstab D, et al.(1996): Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo . *Circ Res.*;79(4):812–820.

Friedmann J.M., Dill J., Hayden, M.R. and McGillivray, B.C. (1992): Transcription of DNA. *Nucleic Acids Research* ; 20 : 961-974.

Frisch L. (1989): The mechanism of protein synthesis. *Coldspring Harb Symp Quant Biol* ; 34: 41.

Gardlik, Roman, Roland Pálffy., Július Hodosy., Ján Lukács, Ján Turňa and Peter Celec. (2005): Vectors and delivery systems in gene therapy. *Medical Science Monitor* ; 11 (4): 110–121.

- Garlson B.M. (1999):** Genetic control of cell function. Human embryology and developmental biology , 2nd (ed). Mosby. St. Louis ; 128–145.
- Geddes B.J., Harding T.C., Lightman S.L. and Uney J.B. (1997):** Long term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nature Medicine ; 3: 1402-1404.
- Gelband C H, Katovich M J, Raizada M K.(2002):** Current perspectives on the use of gene therapy for hypertension. Circ Res; 87(12):1118–1122.
- Gelehrter T.D. and Francis S. (1992):** Molecular genetics: gene organization, regulation, and manipulation. Principles of Medical Genetics ,2 nd (ed).Williams and Wilkins. Baltimore ; 72-82.
- Geller A.I., During M.J., Oh J.Y., Freese F. and OMalley K. (1995):** An HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-DOPA from cultured rat striatal cells. Journal of Neurochemistry ; 64: 487-496.
- George S J, Chester A H, Springall D R, et al(2000):.** Explanted vein grafts with an intact endothelium demonstrate reduced focal expression of endothelial nitric oxide synthase specific to atherosclerotic sites. J Pathol ;179(2):197–203.
- George S J, Lloyd C T, Angelini G D, Newby A C, Baker A H. (2002):** Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation; 101(3):296–304.

- George S J, Angelini G D, Capogrossi M C, Baker A H. (2003):** Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. *Gene Ther*;8(9):668–676.
- George S J, Johnson J L, Angelini G D, Newby A C, Baker A H.(2004):** Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. *Hum Gene Ther* ;9(6):867–877.
- Ghazizadeh S., Carroll J. M. and Taichman L. B. (1997):** Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy. *Journal of Virology*; 71: 9163-9169.
- Glimm H., Kiem H.P., Darovsky B., Storb R., Wolf J., Diehl V., Mertelsmann R. and Kalle C.V. (1997):** Efficient gene transfer in primitive CD34+/CD38^{lo} human bone marrow cells reselected after long term exposure to GALV-pseudotyped retroviral vector. *Human Gene Therapy*; 8: 2079-2086.
- Glorioso J.C., De Luca N.A. and Fink D.J. (1995):** Development and application of herpes simplex virus vectors for human gene therapy. *Annu Rev Microbiol* ; 49: 675-710.
- Gottesman M.M. (2003):** Cancer gene therapy: an awkward adolescence. *Cancer Gene Ther* ; 10: 501–8.
- Gowdak L H, Poliakova L, Wang X, et al.(2000):** Adenovirus-mediated VEGF₁₂₁ gene transfer stimulates angiogenesis in normoperfused

skeletal muscle and preserves tissue perfusion after induction of ischemia. *Circulation* ;102(5):565–571.

Graham F.L., Smiley J., Russell W.L. and Nairn R. (1997): Characterization of a human cell line transformation by DNA from adenovirus. *General Virology*; 36: 59-72.

Grez M., Ott M. and Stein S. (2005): Correction of chronic granulomatous disease by gene therapy. *Mol Ther* ; 11: S130-131.

Grimm D. and Kay M.A. (2003): From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. *Curr Gene Ther* ; 3: 281-304.

Grines C L, Watkins M W, Helmer G, et al.(2004): Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. *Circulation* ;105(11):1291–1297.

Grossman M, Rader D J, Muller D, et al.(1995): A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. *Nat Med*.;1(11):1148–1154.

Guyton A.C and Hall J.E. (2000):Genetic control of cell function. *Textbook of medical physiology* ,10th (ed) W.B. Saunders. Philadelphia ; 24–37.

Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C. and De Villartay J.P.(2002): Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. *N Engl J Med* ; 346: 1185-93.

- Hacein-Bey-Abina S., von Kalle C., Schmidt M. (2003):** A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. *N Engl J Med* ; 348: 255-256.
- Hahn W.C. and Weinberg R.A. (2002):** Modelling the molecular circuitry of cancer. *Nat Rev Cancer* ; 2: 331-341.
- Hanawa H., Hargrove P.W. and Kepes S. (2004):** Extended β -globin locus control region elements promote consistent therapeutic expression of a γ -globin lentiviral vector in murine β -thalassemia. *Blood* ; 10: 1182-1183.
- Harris J. D. and Lemoine N. R. (1996):** Strategies for targeted gene therapy. *Trends in Genetics* ; 12: 400-404.
- Harris J D, Schepelmann S, Athanasopoulos T, et al.(2004):** Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. *Gene Ther* ;9(1):21–29.
- Harris J D, Graham I R, Schepelmann S, et al.(2004):** Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE. *Hum Mol Genet* ; 11(1):43–58.
- Harris P. and Dayan A. (1998):** Designing a safety evaluation programme for gene therapy products: recommendations and the way forward, *Hum Exp Toxicol* ; 17: 63-83.

- Herzog R.W., Hagstrom J. N., Kung S., Tai S. J., Wilson J. M., Fisher K.J. and High K. A. (1997):** Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. *Proc Natl Acad Sci .U.S.A* ; 94: 5804-5809.
- Herzog R.W., Yang E.Y. and Couto, L.B. (1999):** Long-term correction of canine hemophilia B by gene transfer of blood coagulation Factor IX mediated by adeno-associated viral vector. *Nature Med* ; 5: 56-63.
- Herzog R.W., Mount J.D., Arrudavr, High K.A. and Lothrop C.D. Jr. (2001):** Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. *Mol Ther* ; 4:192-200
- Herzog R.W., Fields P.A. and Arruda V.R. (2002):** Influence of vector dose on Factor IX-specific T and B cell responses in muscle-directed gene therapy. *Hum. Gene Ther* ; 13:1281-1291.
- High K.A. and Benz E.F. (1985):** The ABCs of molecular genetics : a haematologist's introduction. In: Hoffbrand, A.V (ed). *Recent Advances in Haematology* 4th(ed). Churchill livingstone . N.Y; 2528.
- Horn P.A., Morris J.C. and Bukovsky A.A. (2002):** Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. *Gene Ther* ; 9: 1464-1471.

- Hu Y, Baker A H, Zou Y, Newby A C, Xu Q.(2003):** Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. *Arterioscler Thromb Vasc Biol.* 2003;21(8):1275–1280.
- Huisman T.H.J. (1996):** Molecular genetics of α -thalassemia. In: McArthur R.J., Lee S.H., Wong J.E.L, Ong Y.W.(eds). *Haematology. Education Programme of the 26th congress of the International Society of Haematology.* Singapore ; 233-6.
- Imren S., Fabry M.E. and Westerman K.A. (2004):** High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. *J. Clin. Invest* ; 114: 953-962.
- Isner J M, Vale P R, Symes J F, Losordo D W.(2003):** Assessment of risks associated with cardiovascular gene therapy in human subjects. *Circ Res* ;89(5):389–400.
- Jaffe, A, Bush, A, Geddes, DM, et al (1999):** Prospects for gene therapy in cystic fibrosis. *Arch Dis Child* ;80,286-289
- Jaffe H A, Danel C, Longenecker G, et al.(1992):** Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. *Nat Genet.*;1(5):372–378.
- Jooss K., Yang Y. and Wilson J.M. (1996):** Cyclophosphamide diminishes inflammation and prolongs expression following

delivery of adenoviral vectors to mouse liver and lung. *Human Gene Therapy* ; 7: 1555-1566.

Juan S H, Lee T S, Tseng K W, et al.(2003): Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. *Circulation* ;104(13):1519–1525.

Karlsson S.(1991): Treatment of genetic defects in hematopoietic cell function by gene transfer. *Blood* ; 78: 2481.

Kato K., Nakanishi M., Kaneda Y., Uchida T. and Okada K. (1991): Expression of hepatitis B virus surface antigen in adult rat liver: co-introduction of DNA and nuclear protein by a simplified liposome method. *Journal of Biological Chemistry* ; 266: 3361-3364.

Kay M.A., Landen C.N., Rothenberg S.R., Taylor L.A., Leland F., Wiehle S., Fang B., Bellinger D., Finegold M., Thompson A.R., Read M., Brinkhous K.M. and Woo, S.L.C. (1994): Adenovirus Vectors, *Proc. Natl. Acad. Sci. USA*; 91: 2353-2357.

Kay M. A., Meuse L., Gown A.M., Linsley P., Hollenbaugh D., Aruffo A., Ochs H.D. and Wilson C.B. (1997): Transient immunomodulation with anti-CD40 ligand and CTLA41g enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. *Proc Natl Acad Sci . U.S.A* ; 94: 4686-4691.

Kay M.A., Manno C.S., Ragni M.V., Larson P.J., Couto L.B. and McClelland (2000): Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector. *Nat Genet*; 24:257-61.

- Kennedy P.G.E. (1997):** Potential uses of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. *Brain* ; 120: 1245-1259.
- Kesari S., Randazzo B.P., Valyi-Nagy T., Huang Q.S., Brown S.M., MacLean A.R., Lee V.M., Trojanowski J.Q. and Fraser N. W. (1995):** Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. *laboratory Investigation* ;73: 636-648.
- Khorana H.G. (1968):** Synthesis in the study of nucleic acids. *Biochem J* ; 109: 709-725.
- Kibbe M R, Billiar T R, Tzeng E.(2000):** Gene therapy for restenosis. *Circ Res* ;86(8):829–833.
- Kibbe M R, Tzeng E, Gleixner S L, et al.(2003):** Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. *J Vasc Surg* ;34(1):156–165.
- Kim I H, Jozkowicz A, Piedra P A, Oka K, Chan L.(2001):** Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. *Proc Natl Acad Sci USA* ;98(23):13282–13287.
- Kim S.H., Yu S.S., Park J.S., Robbins P.D, An C.S. and Kim S. (1998):** Construction of retroviral vectors with improved safety, gene expression, and versatility. *Journal of Virology* ; 72: 994-1004.

- Kim V.N., Mitrophanous K. and Kingsman S.M. (1998):** Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. *J Virol* ; 72: 811-816.
- Kim Y., Lim H. and Kim. (1998):** Production of high titer retroviral vectors and detection of replication-competent retroviruses. *Cells* ; 8:36-42.
- Kimura B, Mohuczy D, Tang X, Phillips M I.(2004):** Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense. *Hypertension* ;37(pt 2):376–380
- Kishi T, Hirooka Y, Ito K, Sakai K, Shimokawa H, Takeshita A.(2004):** Cardiovascular effects of overexpression of endothelial nitric oxide synthase in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. *Hypertension* ;39(2):264–268.
- Klimatcheva, E, Rosenblatt, JD, Planelles, V (1999):**Lentiviral vectors and gene therapy. *Front Biosci* ;4,D481-D496
- Kingston H.M. (1989):** ABC of clinical genetics. *Br Med J* ; 49: 25-28.
- Kingston P a, Sinha S, David a, Castro M G, Lowenstein P R, Heagerty A M.(2003):** Adenovirus-mediated gene transfer of a secreted transforming growth factor- β type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition. *Circulation* ;104(21):2595–2601

- Klein T.M. and Fitzpatrick-McElligott S.F.(1993):** Particle bombardment: a universal approach for gene transfer to cells and tissues. *Current Opinion in Biotechnology* ; 4: 583-590.
- Klugherz B D, Jones P L, Cui X, et al.(2000):** Gene delivery from a DNA controlled-release stent in porcine coronary arteries. *Nat Biotechnol.*;18(11):1181–1184.
- Kochanek S., Schiedner G. And Volpers C.(2001):** High-capacity ‘gutless’ adenoviral vectors. *Curr Opin Mol Ther* ; 3: 454-463.
- Koeberl D D, Alexander I E, Halbert C L, Russell D W, Miller A D.(1997):** Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. *Proc Natl Acad Sci USA.* 1997;94(4):1426–1431.
- Kotin R.M. and Berns K.I. (1989):** Organization of adeno-associated virus DNA in latently infected Detroit 6 cells. *Virology* ; 170: 460-467.
- Kotin R.M., Siniscalco M. and Samulski R.J. (1990):** Site-specific integration by adeno-associated virus. *Proc Natl Acad Sci USA*; 87:2211-2215.
- Kotin R.M., Menninger J.C. and Ward D.C. (1991):** Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. *Genomics* ; 10: 831-834.

- Kotin R.M., Linden R.M. and Berns KI. (1992):** Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. *EMBO J* ; 11:5071-5078.
- Kramm C.M., Chase M., Herrlinger U., Jacobs A., Pechan P. A., Rainov N.G., Sena-estebes M., Aghi M. , Barnett F.H., Chiocca E.A. and Breakefield X.O. (1997):** Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. *Human Gene Therapy* ; 8: 2057-2068.
- Kren, BT, Metz, R, Kujmar, R, et al(1999):** Gene repair using chimeric RNA/DNA oligonucleotides. *Semin Liver Dis* ;19,93-104
- Kucharizuk J.C., Randazzo B., Chang M.Y., Amin K.M., Elshami A. A., Stermann D.H., Rizk N.P., Molnar-Kimber K.L., Brown S.M., MacLean A. R., Litzky L. A., Fraser N.W., Albelda S.M. and Kaiser L. R.(1997):** Use of a replication-restricted herpes virus to treat experimental human malignant mesothelioma. *Cancer Research* ; 57: 466-471.
- Kumar M.B, Keller.N, Makalou, and R.E. Sutton. (2001):** Systematic determination of the packaging limit of lentiviral vectors. *Hum. Gene Ther* ; 12:1893–1905.
- LaFace D.M. and Yu M. (1997):** Gene Therapy for HIV/AIDS: Where Are We Going? *The AIDS Reader*; 7: 184-190.

- Laitinen M, Makinen K, Manninen H, et al.(2000):**Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. *Hum Gene Ther* ;9(10):1481–1486.
- Lasic D.D. and Papahadjopoulos D. (1995):** Liposomes revisited. *Science* ; 267: 1275-1276.
- Laufs S., Gentner B. and Nagy K.Z. (2003):** Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. *Blood* ; 101:2191-2198.
- Leder P. and Nirenberg M. (1964):** RNA codewords and protein synthesis. *Science* ; 145: 1399-1407.
- Lee R J, Springer M L, Blanco-Bose W E, Shaw R, Ursell P C, Blau H M. VEGF(2002):** gene delivery to myocardium: deleterious effects of unregulated expression. *Circulation* ;102(8):898–901.
- Levine F. and Leibowitz G. (1999):** Towards gene therapy of diabetes mellitus. *Mol Med Today* ; 4: 165-71.
- Lewin B (1990):** How many genes in the humn genom? *Nature Genetics*;7:345-346.
- Liu, F, Qi, H, Huang, L, et al (1997):** Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. *Gene Ther* ;4,517-523
- Liu X.Y., Gu J.F. and Shi W.F. (2005):** Targeting gene-virotherapy for cancer. *Acta Biochim Biophys Sin* ; 37: 581-7.
- Look, DC, Brody, SL(1999):** Engineering viral vectors to subvert the airway defense response. *Am J Respir Cell Mol Biol* ;20,1103-1106

- Losordo D W, Vale P R, Symes J F, et al.(1998):** Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF₁₆₅ as sole therapy for myocardial ischemia. *Circulation* ;98(25):2800–2804.
- Lu Q.L., Bou-Gharios G. and Partridge T.A. (2003):** Non-viral gene delivery in skeletal muscle: a protein factory. *Gene Ther* ; 10:131-142.
- Macilwain C. (2000):** World leaders heap praise on human genome landmark. *Nature* ; 405: 983-984.
- Maeda Y., Ikeda U., Ogasawara Y., Urabe M., Takizawa T., Saito T., Colosi P., Kurtzman G., Shimada K. and Ozawa K. (1997):** Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. *Cardiovascular Research* ; 35: 514-521.
- Maki H. (2002):** Origins of spontaneous mutations: specificity and directionality of base-substitution, frameshift, and sequence-substitution mutagenesis. *Annual Review of Genetics* ; 36:279-303.
- Malech H., Maples P. and Whiting-Theobald N. (1997):** Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. *Proc Natl Acad Sci*; 94: 12133–12138.
- Mann M J, Whittemore A D, Donaldson M C, et al.(2001):** Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. *Lancet* ;354(9189):1493–1498.

- Manno C.S., Pierce G.F. Glader B. (2006):** Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med* ; 12: 342-347.
- Marconi P., Krisky D., Oligino T., Poliani P.L., Ramakrishnan R., Goins W.F., Fink D.A. and Glorioso J.C. (1996):** Replication-defective herpes simplex virus vectors for gene transfer in vivo. *Proc Natl Acad Sci USA* ; 93: 11319-11320.
- Markowitz D., Goff S. and Bank A. (1988):** A safe packing line for gene transfer: separation of viral genes in two different plasmids. *Journal of virology* ; 62: 1120-1124.
- Martinez E. (2002):** Multi-protein complexes in eukaryotic gene transcription. *Plant Mol Biol*; 50: 925-47.
- May C., Rivella S. and Callegari J. (2000):** Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. *Nature* ; 406: 82-86.
- McCormack J.E., Martineau D., DePolo N., Maifert S., Akbarian L., Townsend K., Lee W., Irwin M., Sajjadi N., Jolly D.J. and Warner J. (1997):** Anti-vector immunoglobulin induced by retroviral vectors. *Human Gene Therapy* ; 8: 1263-1273.
- Mckusick A.V. (1987):** The morbid anatomy of the human genome : A review of gene mapping in clinical medicine. *Medicine* ;66: 1.
- Mehta S R, Eikelboom J W, Rupprecht H J, et al.(2004):** Efficacy of hirudin in reducing cardiovascular events in patients with acute

coronary syndrome undergoing early percutaneous coronary intervention. *Eur Heart J* ;23(2):117–123.

Melo L G, Agrawal R, Zhang L, et al.(2004): Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. *Circulation* ;105(5):602–607.

Merrouche Y., Negrier S., Bain C., Combaret V., Mercatello A., Coronel B., Moskovtchenko J.F., Tolstoshev P., Moen R. and Philip T.(1995): Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. *J Clin Oncol* ; 2:408-410.

Miller D.G., Adam M.A. and Miller A.D.(1990): Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. *Mol Cell Biol* ; 10: 4239-4242.

Miller R.H. And Sarver N(1997): HIV accessory proteins as therapeutic targets. *Nat Med* ;3:389-394.

Morgan DO. (2007): The Cell Cycle. http://en.wikipedia.org/wiki/Cell_cycle

Morishita R, Aoki M, Kaneda Y.(2000): Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs? *Curr Drug Targets* ;1(1):15–23.

Muruve D.A. (2004): The innate immune response to adenovirus vectors. *Hum. Gene Ther* ; 15: 1157-1166.

Nabel E G, Plautz G, Nabel G J.(1990): Site-specific gene expression in vivo by direct gene transfer into the arterial wall. *Science* ;249(4974):1285–1288.

Nabel, GJ, Hobart, P Meeting report(1998): Keystone Symposia on molecular and cellular biology of gene therapy and synthetic non-viral gene delivery systems. *Biochem Biophys Acta* 1998;1378,R19-R26

Nakai H., Montini E., Fuess S., Storm T.A., Grompe M. and Kay M.A. (2003): AAV serotype 2 vectors preferentially integrate into active genes in mice. *Nat Genet* ; 34: 297-302.

Nakane H, Miller F J. Jr, Faraci F M, Toyoda K, Heistad D D.(2002): Gene transfer of endothelial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction. *Hypertension* ; 35(2):595–601.

Naldini L., Blomer U. and Gallat P. (1996): In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. *Science* ; 272: 263-267.

National Cancer Institute (2004): Gene therapy for cancer: Questions and answers, (2004, March 3) Retrieved 6 September 6, 2004, from National Cancer Institute Web Site: http://cis.nci.nih.gov/fact/7_18.htm.

Nevins J.R. (1983): The pathway of eukaryotic m RNA .*Annu. Rev Biochem* ; 52: 441.

- Nevin N. and Spink J. (2000):** Gene Therapy Advisory Committee Long Term Monitoring of Patients Participating in Gene Therapy. *Human Gene Therapy* ; 11: 1253-1255.
- Newstead C.G.(1998):** Assessment of risk of cancer after renal transplantation. *Lancet* ; 351: 623-628.
- Nienhuis A.W., Wals C.E. and Liu J.M. (1995):** Gene therapy for hematological disorders. In: Hoffman Ronald; Benz Edward J.; Frui Bruce (ed) .*Hematology Basic principles and practice*. 2nd (ed). Churchill-livingston . Inc ;250.
- Nishida T, Ueno H, Atsuchi N, et al.(2001):** Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. *Circ Res*. 2001;84(12):1446–1452.
- Ohno N, Itoh H, Ikeda T, Ueyama K, et al.(2004):**Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. *Circulation*. 2004;105(14):1623–1626.
- Okazaki R., Okazaki T., Sakabe K., Sugimoto K. and Sugino A. (1968):** Mechanism of DNA chain growth, I. Possible discontinuity unusual secondary structure of newly synthesized chains. *Proc Natl Acad Sci USA* ; 59: 598-605.

Ott M.G., Grez M. and Stein S. (2005): Long-term follow-up of patients treated by gene therapy for X-linked chronic granulomatous disease. *Blood* ; 106: 60.

Panetta C J, Miyauchi K, Berry D, et al.(2002):A tissue-engineered stent for cell-based vascular gene transfer. *Hum Gene Ther* ;13(3):433–441.

Pannell D. and Ellis J.(2001): Silencing of gene expression: implications for design of retrovirus vectors. *Rev Med Virol* ; 11: 205-217.

Pasi K.J. (2001): Gene therapy for hemophilia. *Br J Haematol* ; 115(4):744-57.

Paul S.(1999): Tighter watch urged on adenoviral vectors. *Nature* ; 402: 707.

Pawliuk R. and Leboulch P. (2001): Correction of sickle cell disease in transgenic mouse models by gene therapy. *Science* ; 294 (14): 2368-2371.

Pear W.S., Nolan G.P. and Scott M.L.(1993): Production of helper- free retroviruses by transient transfection. *Proc Natl Acad Sci USA* ; 90: 8392-8396.

Peltonen., Leena., Victor A and McKusick. (2001): "Dissecting Human Disease in the Postgenomic Era." *Science* ; 291: 1224-1229.

Persons D.A., Allay E.R. and Sawai N. (2003): Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. *Blood* ; 102: 506-513.

- Phillips M I, Wielbo D, Gyurko R.(1994):** Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. *Kidney Int.* 1994;46(6):1554–1556.
- Phillips M I, Tang Y, Schmidt-Ott K, Qian K, Kagiya S. Vigilant vector(2004):**heart-specific promoter in an adeno-associated virus vector for cardioprotection. *Hypertension.* 2004;39(pt 2):651–655.
- Phillips M I.(2001):** Is gene therapy for hypertension possible? *Hypertension.* 2001; 33(1):8–13.
- Phillips M I.(2004):** Gene therapy for hypertension: the preclinical data. *Methods Enzymol.* 2004; 346:3–13.
- Phillips M I, Mohuczy-Dominiak D, Coffey M, et al.(2001):** Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense. *Hypertension.* 2001; 29(1 Pt 2):374–380.
- Podsakoff G., Wong K.K. Jr. and Chatterjee S.(1994):** Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. *J Virol* ; 68: 5656-5666.
- Ponder K P.(1999):** Systemic gene therapy for cardiovascular disease. *Trends Cardiovasc Med.* 1999;9(6):158–162.
- Prince, HM (1998):** Gene transfer: a review of methods and applications. *Pathology* 30,335-347

Quarck R, De Geest B, Stengel D, et al.(2003):Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. *Circulation* ; 103(20):2495–2500.

Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel E G. (2001):Adenovirus-mediated gene transfer of VEGF₁₂₁ improves lower-extremity endothelial function and flow reserve. *Circulation* ;104(7):753–755.

Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A. and Gao G.P. (2003): Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. *Mol Genet Metab* ; 80: 148-58.

Rech E.L., De Bem R. and Aragão F.J.L. (1996): Biolistic-mediated gene expression in guinea pigs and cattle tissues in vivo. *Brazilian Journal of Medical and Biological Research* ; 29: 1265-1267.

Rinaudo D, Lamartina S, Roscilli G, Ciliberto G, Toniatti C.(2000) Conditional site-specific integration into human chromosome 19 by using a ligand-dependent chimeric adeno-associated virus/Rep protein. *J Virol* ;74(1):281–294.

Rollins S.A., Birks C.W., Setter E., Squinto S, P. and Rother R. P. (1996): Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for

evading the humoral immune response. *Human Gene Therapy* ; 7: 619-626.

Romano G., Guan M. and Long W.K. (1997): Differential effects on HIV-1 gene regulation by EBV in T lymphocytic and promonocytic cells transduced to express recombinant human CR2 (CD21). *Virology* ; 237: 23-32.

Rosenberg S.A., Aebersold P. and Cornetta K. (1990): Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *N Engl J Med* ; 323: 570-578.

Rosenfeld, MA, Siegfried, W, Yoshimura, K, et al(1991): Adenovirus-mediated transfer of recombinant α_1 -antitrypsin gene to the lung epithelium in vivo. *Science* ;252,431-434

Rosengart T K, Lee L Y, Patel S R, et al.(2000): Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF₁₂₁ cDNA to individuals with clinically significant severe coronary artery disease. *Circulation* ;100(5):468–474.

Roth D.A., Tawa N.E. Jr., O'Brien J.M., Treco D.A. and Selden R.F. (2001): Non-viral transfer of the gene encoding coagulation Factor VIII in patients with severe hemophilia. *A N Engl J Med* ; 344: 1735-1742.

Rother P.R, William L.F., and Rollins S.A (1995): A novel mechanism of retrovirus inactivation in human serum mediated by anti a

galactosyl nature antibody. *Journal of Experimental Medicine* ; 182:1345-1355.

Rouis M, Adamy C, Duverger N, et al.(2001): Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. *Circulation* ; 100(5):533–540.

Rubin E. and Farber J.L. (1999): Genetic control of cell function . Pathology, 3rd (ed). Williams and Wilkins. Philadelphia; 260.

Rutledge E.A. and Russell D.W. (1997): Adeno-associated virus vector integration junctions. *Journal of Virology* ; 71: 8429-8436.

Sadelain M., Rivella S., Lisowski L., Samakoglu S. and Riviere I (2004): Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease. *Best Pract Res Clin Haematol* ; 17:517-534.

Saleh, M. (1997): A retroviral vector that allows co-expression of two genes and the versatility of alternate selection markers. *Human Gene Therapy* ; 8: 979-983.

Samulski, R.J., Chang L., and Shenk T. (1989): Helper free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. *Journal of Virology* ; 63: 3822-3828.

Sanford J.C., Klein T.M., Wolf E.D. and Allen N. (1987): Delivery of substances into cell tissues using a particle bombardment process. *Particulate Science and Technology* ; 5: 27-37.

- Scallan C.D., Lillicrap D. and Jiang H. (2003):** Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. *Blood*; 102: 2031-2037.
- Scanlon K.J. (2004):** Cancer gene therapy: challenges and opportunities. *Anticancer Res* ; 24: 501-4.
- Schmidt M., Schwarzwaelder K. and Ott M. (2005):** Stable polyclonal hematopoietic repopulation after successful clinical gene therapy of chronic granulomatous disease (CGD). *Mol Ther* ; 11: 415.
- Scheule, RK, George, JA, Bagley, RG, et al(1997):** Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. *Hum Gene Ther* 1997;8,689-707
- Schuettrumpf J., Herzog R.W., Schlachterman A., Kaufhold A., Stafford D.W. and Arruda V.R. (2005):** Factor IX variants improve gene therapy efficacy for hemophilia B. *Blood* ; 105:2316-2323.
- Schwartz L B, Moawad J, Svensson E C, et al.(2001):** Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. *J Vasc Surg*. 2001;29(5):874–881.
- Shapiro L.J. (2000):** Molecular basis of genetic disorders. In Behrman , R.E., Kliegman R.M., Jenson H (eds.). *Nelson’s textbook of pediatrics*, 16th (ed).W.B. Saunders. Philadelphia; 313–317.
- Shimpo M, Ikeda U, Maeda Y, et al.(2004):** AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves

blood flow in a rat hindlimb ischemia model. *Cardiovasc Res* ;53(4):993–1001.

Simons and Michael M.D. (2000): Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus: An Expert Panel Summary. American Heart Association, Inc ; 11: 73-86.

Sirakoulis G., Karafyllidis I., Sandaltzopoulos R. and Tsalides P.H. (2004): An algorithm for the study of DNA sequence evolution based on the genetic code. *Biosystems* ; 77: 11-23.

Smith A.E. (1995): Viral vectors in gene therapy. *Annual Review of Microbiology* ; 49: 807-838.

Smith K.T., Shepherd A. J., Boyd J.E. and Lees G.M. (1996): Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. *Gene Ther* ; 3: 190-200.

Smith L. and Byers J.F. (2002): Gene therapy in the post-Gelsinger era. *JONAS Healthc Law Ethics Regul* ; 4: 104-110.

Snyder R.O., Miao C. H., Patijn G. A., Spratt S. K., Danos O., Nagy D., Gown A.M., Winter B., Meuse L., Cohen L.K., Thompson A. R. and Kay M.A. (1997): Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. *Nature Genetics* ; 16: 270-275.

Sorgi, FL, Bhattacharya, S, Huang, L(1997): Protamine sulfate enhances lipid-mediated gene transfer. *Gene Ther* ;4,961-968

- Sorrentino B.P. (1992):** Selection of Drug-Resistant Bone Marrow Cells in Vivo After Retroviral Transfer of Human MDR1. *Science* ; 257: 99-103.
- Springer M L, Chen A S, Kraft P E, Bednarski M, Blau H M. VEGF(2000):** gene delivery to muscle: potential role for vasculogenesis in adults. *Mol Cell* ;2(5):549–558.
- Stamatoyannopoulos J.A.(1992):** Future prospects for treatment of hemoglobinopathies. *West J Med Dec* ; 157 (6): 631–636.
- Stankovics J., Crane A.M., Andrews E., Wu C.H., Wu G.Y. and Ledley F.D. (1994):** Overexpression of human methylmalonyl CoA mutase in mice after in vivo gene transfer with asialoglycoprotein/polylysine/DNA complexes. *Human Gene Therapy* ; 5: 1095-1104.
- Stasiak A. (1996):** Getting down to the core of homologous recombination. *Science* ; 272: 828-9.
- Stein C.S., Kang Y. and Sauter S.L. (2001):** In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. *Mol Ther* ; 3: 850-856.
- Steinberg M.H. (1999):** Management of sickle cell disease. *N Engl J Med* ; 340: 1021-1030.
- Steiner I., Spivack J.G., Lirette R.P., Brown S.M., MacLean A. R., Subak-Sharpe J.H. and Fraser N.W. (1989):** Herpes simplex virus type 1 latency-associated transcripts are evidently not evidently not essential for latent infection.*EMBO Journal* ; 8: 505-511.

Stewart P.L., Fuller S.D. and Burnett R.M.(1993): Difference imaging of adenovirus: bridging the resolution gap between x-ray crystallography and electron microscopy. *EMBO J* ; 12: 2589-2599

Su H, Lu R, Kan Y W.(2002): Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. *Proc Natl Acad Sci USA*; 97(25):13801–13806.

Tait D. L., Obermiller P. S., Redlin-Frazier S., Jensen R.A., Welcsh P., Dann J., King M, Johnson D.H. and Holt J. T. (1997): A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. *Clinical Cancer Research* ; 3: 1959-1968.

Takeuchi Y., Cosset F.L. and Lackmann P.J. (1994): Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. *J Virol* ; 68: 8001-8007.

Taniyama Y, Univ O, Jsapan S, et al.(2000): Local delivery of naked plasmid DNA of p53 gene into rat balloon injured carotid artery using low voltage ultrasound with contrast microbubbles (optison): development of novel non-viral transfection system into blood vessels. *Circulation* ;102(suppl II):II–164 abstract.

Thein S.L. (1996): Molecular genetics of β -thalassaemia. In: McArthur J.R., Lee S.H., Wong J.E.L., Ong Y.W.(eds). *Haematology. Education Programme of the 26th congress of the International Society of Haematology*. Singapore: ICH ;236-40.

- Thorne, PS, McCray, PB, Howe, TS, et al(1999):** Early inflammatory responses in vivo to adenoviral vectors in the presence or absence of LPS-induced inflammation. *Am J Respir Cell Mol Biol* ;20,1155-1164
- Thompon M.W, Mcinne R. and Willard H.F. (1991):** Role of genetics in medicine . In Wonsiewicz, M.I.(ed). *genetics in medicine* 5th (ed).W.B Saunders. Philadelphia ; 550.
- Tisdale J.F., Dunbar C.E. and Goodman S.A. (1998):** Gene therapy for hematological disorders, HIV infection, and cancer. In G. R. Lee, J. Foerster, R. Greer, J. Lukens, G. Rodgers and F. Paraskevas.(eds). *Wintrobe's Clinical Hematology*. Williams and Wilkins. Philadilphia; 2178-2208.
- Tseng W.C. and Huang L. (1998):** Liposome-based gene therapy. *Pharmaceut Sci Technol Today* ; 1: 206-13.
- Tsurumi Y, Takeshita S, Chen D, et al.(1996):** Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. *Circulation* ;94(12):3281–3290.
- Tyler, RC, Fagen, K, Unfer, R, et al(1999):** Endovascular inflammation inhibits transgene expression in the pulmonary circulation in vivo. *Am J Physiol* ;277,L1119-L1204
- Vassalli G, Dichek D A.(1997):** Gene therapy for arterial thrombosis. *Cardiovasc Res* ;35(3):459–469.

- Verdier F. and Descotes J. (1999):** Preclinical Safety Evaluation of Human Gene Therapy Products, Toxicological Sciences. Society of Toxicology ; 47: 9-15.
- Verma, I.M. (1990):** Gene therapy. Sci Am ; 263: 68-72.
- Verma I.M. and Somia N. (1997):** Gene therapy – Promises, Problems and Prospects. Nature ; 389:239-242.
- Vulliamy T. J.D. ,Urso M. And Battistuzzi G. (1988):** Diverse point mutations in the human glucose 6-phosphate dehydrogenase gene cause enzyme deficiency and mild or sever hemolytic anemia. Proc Natl Acad Sci USA ; 85: 5171.
- Wagner R.P., Judd B.G., Sanders B.G. and Richardson R.H. (1980):** Introduction to modern genetics. Immunol Today ; 72: 18-22.
- Wang S. and Vos J. (1996):** A hybrid herpes virus infectious vector based on epstein-barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. Journal of Virology ; 70: 8422-8430.
- Wang L., Muramatsu S. and Lu Y. (2002):** Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther ; 9: 381-389.
- Watson J.D. and Grick F.H.C. (1953):** Genetic implicatins of the structure of deoxy ribonucleic acid. Nature ; 177: 964.
- Waugh J M, Kattash M, Li J, et al(2001):.** Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen

activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA. 2001;96(3):1065–1070.

Waugh J M, Yuksel E, Li J, et al.(2001): Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res. 2001;84(1):84–92.

Weatherall D.J. and Clegg J.B. (1996): Thalassemia—a global public health problem. Nature Med ; 3: 47-9.

West N E, Qian H, Guzik J J, et al.(2003): Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation ;104(13):1526–1532.

Wheeler M D, Katuna M, Smutney O M, et al.(2003): Comparison of the effect of adenoviral delivery of three superoxide dismutase genes against hepatic ischemia-reperfusion injury. Hum Gene Ther ;12(18):2167–2177.

Williams D. (2001): Clarity and risk: the challenges of the new technologies. Med Device Technol ; 12: 4-12.

Winkelstein J.A., Marino M.C. and Johnston R.B. (2000): Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine ; 3: 155-69.

Www.csmate.colostate.edu/.../Transcription.gif.

Www.faculty.clintoncc.suny.edu/.../gene.h3.gif.

Www.genome.wellcome.ac.uk/assets/GEN10000674.jpg.

Www.images1.clinicaltools.com/images/gene/mrnatex .

Www.infohost.nmt.edu/~klathrop/DNA%20Coiling.jpg.

Www.members.tripod.com/.../images/dna10.jpg.

Www.mindfully.org/GE/Human-Genome4.GIF.

Www.teachline.ls.huji.ac.il/.../cell-cycle2.jpe.

Xiao X, Li J, Samulski R J.(1996): Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. *J Virol* ;70(11):8098–8108.

Yang X, Atalar E, Li D, et al.(2001):Magnetic resonance imaging permits in vivo monitoring of catheter-based vascular gene delivery. *Circulation* ;104(14):1588–1590.

Yang, Y, Trinchieri, G, Wilson(1996): JM Recombinant IL-12 prevents formation of blocking antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. *Nat Med* ;9,890-893

Ye S., Cole-Strauss A., Frank B. and Kmiec E.B. (1998): Targeted gene correction: a new strategy for molecular medicine. *Mol Med Today* ; 4: 10:431-7.

Yee J.K., Miyanoharo A., Laporte P., Bouic K., Burns J. C. and Friedmann T. (1994): A general method for the generation of high titre, pantropic retroviral vectors: high efficient infection of primary hepatocytes. *Proc Natl Acad Sci* ; 91: 9564-8.

- Yei S., Mittereder N. and Tang K .(1994):** Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. *Gene Ther* ; 1:192-200.
- Yi-Lin Liu., Federico Mingozzi,, Sol M., Rodriguez-Colon., Sasha Joseph., Eric Dobrzynski., Takashi Suzuki., Katherine A., High, Roland W and Herzog (2004):** Therapeutic Levels of Factor IX Expression Using a Muscle-Specific Promoter and Adeno-Associated Virus Serotype 1 Vector. *Human Gene Therapy* ; 15: 8, 783
- Yla-Herttuala S, Martin J F.(2000):**Cardiovascular gene therapy. *Lancet* ;355(9199):213–222.
- Young S M. Jr, McCarty D M, Degtyareva N, Samulski R J.(2000):** Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. *J Virol.* 2000;74(9):3953–3966.
- Yu M. (1994):** Gene Therapy for HIV/AIDS. *The AIDS Reader* ; 4: 145-148.
- Zaid A.H.G., Hughes E., Porceddu F. and Nicholas (2001):** Glossary of Biotechnology for Food and Agriculture-A Revised and Augmented Edition of the Glossary of Biotechnology and Genetic Engineering . http://en.wikipedia.org/wiki/Genetic_modification.
- Zatloukal K., Cotton M., Berger M., Schimdt W. and Wagner E. (1994):** In vivo production of human factor VIII in mice after

intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. *Proceedings of the National Academy of Science of the USA* ; 91: 5148-5152.

Zeitlin, PL(2000): Cystic fibrosis gene therapy trials and tribulations. *Mol Ther*;1,5-6

Zhang J J, Wang C, Lin K F, Chao L, Chao J.(2001): Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. *Clin Exp Hypertens* ; 21(7):1145–1160.

Zhang Q. (2005): Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8⁺ T cells: eradication of autologous mouse prostate cancer. *Cancer Res* ; 65: 1761-1769.

Zhu N., Liggitt D., Liu Y. and Debs R. (1993): Systemic gene expression after intravenous DNA delivery into adult mice. *Science* ; 261: 209-211.

Zoldhelyi P, McNatt J, Xu X M, et al.(1998): Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. *Circulation*. 1998;93(1):10–17.

Zoldhelyi P, McNatt J, Shelat H S, Yamamoto Y, Chen Z Q, Willerson J T.(2002): Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. *Circulation* ;101(3):289–295.

Zufferey R., Nagy D. and Mandel RJ (1997):Multiple attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nature Biotechnology* ;15:871-875.